Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2017-06-12 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
独立财务顾问承诺函
Regulatory Filings Classification · 95% confidence The document is titled as an "Independent Financial Advisor Commitment Letter" related to a company's issuance of shares and cash payment for asset acquisition and fundraising. It contains statements of due diligence, compliance with regulations, and confidentiality measures by the financial advisor. There are no financial statements, detailed financial data, or report content. The document is a formal attestation or certification by the financial advisor rather than a financial report or announcement of voting results, management changes, or other categories. It fits best as a Regulatory Filing (RNS) because it is a compliance-related certification document without substantive financial data or report content.
2017-06-12 Chinese
简式权益变动报告书（一）
Major Shareholding Notification Classification · 95% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the changes in shareholding of the company Quantum Hi-Tech (China) Biological Co., Ltd., including information about shareholders increasing their stakes, share issuance, and related agreements. The document includes detailed descriptions of shareholding percentages before and after the transaction, the purpose of the equity change, the method of equity change, contractual details, and regulatory approvals required. It is a comprehensive report on changes in major shareholdings and equity structure rather than a general financial report, earnings release, or management discussion. This matches the definition of "Major Shareholding Notification (Code: MRQ)" which covers notifications of changes in significant share ownership levels crossing thresholds. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or certification, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Therefore, the correct classification is MRQ with high confidence.
2017-06-12 Chinese
董事会关于是否达到中国证监会《关于规范上市公司信息披露及相关各方行为的通知》第五条相关标准的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors of Quantum Hi-Tech (China) Biological Co., Ltd. regarding whether the stock price fluctuations before a trading suspension meet the criteria set by the China Securities Regulatory Commission (CSRC) in their notice on regulating information disclosure and related behaviors. It discusses stock price movements, market indices, and compliance with regulatory standards. The document is not a full financial report, earnings release, or management discussion. It is a regulatory compliance disclosure related to stock price behavior and trading suspension, which fits best under Regulatory Filings (RNS) as it is a regulatory announcement that does not fit other specific categories.
2017-06-12 Chinese
董事会关于本次重大资产重组事项履行法定程序的完备性、合规性及提交法律文件的有效性的说明
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation from the company's board regarding the completeness, compliance, and validity of legal documents submitted for a major asset restructuring transaction. It references the company's board meeting, legal and regulatory compliance, and the process of a significant asset acquisition and related fundraising. The content focuses on the procedural and legal aspects of a major asset reorganization rather than presenting financial statements or audit results. This aligns with announcements related to major asset restructuring and compliance with legal procedures, which is best classified under Capital/Financing Update (CAP). The document length is short (1662 characters) and contains substantive content about the transaction process, not just an announcement of a report or a certification letter, so it is not RPA or RNS. Therefore, the most appropriate classification is CAP.
2017-06-12 Chinese
上海荣正投资咨询有限公司关于公司2017年股票期权激励计划（草案）之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report regarding a 2017 stock option incentive plan for Quantum Hi-Tech (China) Biological Co., Ltd. It includes detailed analysis and opinions on the stock option plan's compliance with laws and regulations, feasibility, scope of incentive recipients, allocation, conditions for granting and exercising options, performance assessment, and financial impact. The document is lengthy (over 14,000 characters) and contains substantive content, not just an announcement. It is not a general annual report, earnings release, or management report but a specialized advisory report on a stock option incentive plan. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through stock option incentives.
2017-06-12 Chinese
股权激励计划自查表
Governance Information Classification · 95% confidence The document is a detailed compliance checklist related to a company's equity incentive plan, including internal controls, legal compliance, performance metrics, and procedural adherence. It does not contain financial statements or results, nor is it an announcement of a report publication. It is not a regulatory filing or certification letter but a compliance and governance-related document. The content focuses on governance and compliance aspects of the equity incentive plan, which aligns best with Governance Information (CGR). The document length is under 5,000 characters but contains substantive content, so it is not a mere announcement. Therefore, the classification is Governance Information (CGR).
2017-06-12 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.